Could a palm extract help fight a rare genetic brain disease?

NCT ID NCT04658823

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a supplement called HOV-12020 (made from palm tocotrienols) in 50 adults aged 45-75 with CADASIL, a rare genetic disease that damages small blood vessels in the brain, leading to strokes and memory loss. The goal was to see if the supplement could reduce worsening of symptoms like stroke, disability, or cognitive decline over 24 months. Participants were randomly assigned to receive either the supplement or a placebo, and neither they nor their doctors knew which they received.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CADASIL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Lariboisière APHP

    Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.